Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04690-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Anita Moein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Fulvestrant, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Receptors, Estrogen. Die Arbeit nennt 56 Literaturangaben. Gefördert von: This work was supported by Genentech Inc., a member of the Roche group..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada.
- Genentech, Inc., South San Francisco, CA, USA.
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada. harvey.wong@ubc.ca.
Förderung
- This work was supported by Genentech Inc., a member of the Roche group.
Zitieren
APA
Moein, A., Jin, J. Y., Wright, M. R., & Wong, H. (2024). Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04690-4
Vancouver
Moein A, Jin JY, Wright MR, Wong H. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04690-4
BibTeX
@article{Moein2024,
author = {Moein, Anita and Jin, Jin Y and Wright, Matthew R and Wong, Harvey},
title = {Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04690-4}
}
EUVIMED